Skip to Main Content

Last June, Amgen excited cancer scientists and investors alike with the first tumor-shrinking results from a medicine targeted against the “undruggable” KRAS protein.

On Sunday, the biotech presented another round of data on the KRAS-blocking drug called AMG 510. Like this past summer, tumor responses hover around 50% — more impressive now because the analysis comprises a larger number of lung cancer patients. But the details also reveal some questions about AMG 510 that will require further time and study to answer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!